News

Public · Published

Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth

Profound Medical announced a supply and distribution agreement with the iMRI Division of Cook Medical to expand U.S. sales of its TULSA-PRO system through Cook's Copernicus program, while Profound keeps direct recurring treatment kit and service revenue relationships for systems Cook sells.

Published:

Updated:

What happened

Profound Medical announced a supply and distribution agreement with the iMRI Division of Cook Medical to expand U.S. sales of its TULSA-PRO system through Cook's Copernicus program, while Profound keeps direct recurring treatment kit and service revenue relationships for systems Cook sells.

Confirmed

Global impact / market context

The deal adds a second U.S. sales channel for TULSA-PRO equipment, letting Profound reach hospitals already building iMRI programs. Because Profound keeps the recurring kit and service revenue, each system sold through Cook can generate repeat income rather than a one-time equipment sale.

Analyst inference

Profound already sells through Siemens Healthineers, and adding Cook broadens distribution without building a larger direct sales force. Hospitals buying the integrated iMRI Suite, which means an MRI procedure room built for real-time image-guided treatment, may consider TULSA-PRO alongside other compatible therapies.

Analyst inference

What to watch

  1. Profound said it retains direct relationships for recurring TULSA-PRO treatment kit and service revenue on systems sold through Cook Medical, so watch whether those repeat payments scale with new placements. Confirmed
  2. Watch U.S. TULSA-PRO system placements through Cook's Copernicus program, since more installed systems would raise future kit and service revenue and show whether the added channel works. Analyst inference
  3. Watch whether Profound discloses sales split between its direct team and partners, and whether the Cook agreement includes minimum purchase targets or exclusivity terms that shape capital spending. Proposed

Evidence